• PIN1- IMPACT OF INFLUENZA AND TREATMENT WITH OSELTAMIVIR ON INDIVIDUALS DAILY ACTIVITIES AND RETURN TO NORMAL ACTIVITY

    Sep 1, 2001, 00:00

  • CV6- EXCESS MORBIDITY AND COST OF FAILING TO ACHIEVE TARGETS FOR BLOOD PRESSURE CONTROL IN THE ELDERLY

    Sep 1, 2001, 00:00

  • PHP2- GASTROINTESTINAL DRUG POLICY, DRUG SELECTION AND RESOURCE UTILIZATION-A COMPARISON OF THE CANADIAN PROVINCES OF QUEBEC AND ONTARIO

    Sep 1, 2001, 00:00

  • PND14- QUALITY OF LIFE OF WOMEN SUFFERING FROM MENSTRUAL MIGRAINE AND RELATIONSHIP WITH MOOD

    Sep 1, 2001, 00:00

  • PHP10- THE POTENTIAL BENEFITS AND DRAWBACKS OF ALLOWING DIRECT-TO-CONSUMER ADVERTISING OF PHARMACEUTICALS IN EUROPE

    Sep 1, 2001, 00:00

  • PDG26- THE IMPACT OF THE USE OF NEXIUM ON THE OVERALL PPI BUDGET IN GREECE

    Sep 1, 2001, 00:00

  • PCV27- COST-EFFECTIVENESS ANALYSIS OF A CHEST PAIN UNIT-A RE-STRUCTURED APPROACH IN RISK STRATIFICATION OF CHEST PAIN

    Sep 1, 2001, 00:00

  • PPN1- AN INTERNET STUDY OF WTP FOR MIGRAINE PHARMACOTHERAPIES

    Sep 1, 2001, 00:00

  • PHP17- A EUROPEAN HEALTH STATUS INDEX BASED ON PREFERENCES OF THE GENERAL PUBLIC

    Sep 1, 2001, 00:00

  • ND3- COST-EFFECTIVENESS OF CABERGOLINE COMPARED TO LEVODOPA IN EARLY PARKINSONS DISEASE IN SWEDEN

    Sep 1, 2001, 00:00

  • PCV14- IMPACT OF OBESITY ON HEALTH-RELATED QUALITY OF LIFE (HRQOL)- AN ANALYSIS OF BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM (BRFSS) DATA

    Sep 1, 2001, 00:00

  • PCN23- DISEASE MODELING- DEVELOPING THE INFRASTRUCTURE FOR A COMPREHENSIVE, MULTI-NATIONAL, CLINICAL AND ECONOMIC BREAST CANCER TREATMENT MODEL

    Sep 1, 2001, 00:00

  • PDG2- RISK OF DIABETES AMONG RISPERIDONE AND OLANZAPINE USERS

    Sep 1, 2001, 00:00

  • PQP9- QUALITY OF LIFE OF PATIENTS WITH FABRY DISEASE

    Sep 1, 2001, 00:00

  • PDB10- THE COST OF NEW ONSET DIABETES MELLITUS AMONG US RENAL TRANSPLANT RECIPIENTS

    Sep 1, 2001, 00:00

  • PCN13- PHARMACOECONOMIC ANALYSIS OF ADVANCED NON-SMALL CELL LUNG CANCER TREATMENT WITH DOCETAXEL-CISPLATIN, PACLITAXEL-CISPLATIN AND PACLITAXEL-CARBOPLATIN

    Sep 1, 2001, 00:00

  • PMH14- DEFICIT SYNDROME AND DRUG USE PATTERNS IN COMMUNITY-BASED SCHIZOPHRENIA CARE

    Sep 1, 2001, 00:00

  • PHP20- THE ECONOMIC BURDEN OF PHYSICAL INACTIVITY IN SWITZERLAND

    Sep 1, 2001, 00:00

  • PMI4- MARKOV MODELLING TO CONVERT TRIAL-BASED COST-EFFECTIVENESS INFORMATION TO OTHER COUNTRIES-THE TIOTROPIUM EXAMPLE

    Sep 1, 2001, 00:00

  • PMH1- SHOULD THE 51 ITEMS OF THE SCHIZOPHRENIA OUTCOMES ASSESSMENT PROJECT (SOAP-51) BE WEIGHTED?

    Sep 1, 2001, 00:00

  • PCV42- PATIENTS WILLINGNESS TO PAY FOR PHARMACIST MANAGED WARFARIN THERAPY AT COMMUNITY PHARMACIES

    Sep 1, 2001, 00:00

  • CN5- A SPECIFIC QUALITY OF LIFE SCALE IN UPPER LIMB LYMPHOEDEMA- THE ULL-27 QUESTIONNAIRE

    Sep 1, 2001, 00:00

  • PMI27- FACTORS INFLUENCING COMPLETION OF THE EUROQOL EQ-5D GENERIC QOL QUESTIONNAIRE

    Sep 1, 2001, 00:00

  • PCN11- ECONOMIC EVALUATION OF LIPOSOMAL DOXORUBICIN VS TOPOTECAN FOR RECURRENT OVARIAN CANCER IN THE UK

    Sep 1, 2001, 00:00

  • PCN4- COST-EFFECTIVENESS OF URATE OXIDASE IN PREVENTION AND TREATMENT OF SEVERE HYPERURICEMIA AND TUMOUR LYSIS SYNDROME IN HAEMATOLOGIC MALIGNANCIES

    Sep 1, 2001, 00:00

  • PCV18- FRAMINGHAM RISK EQUATIONS PREDICT HOSPITAL USAGE AND MORTALITY

    Sep 1, 2001, 00:00

  • PCN7- COST OF THE POST-PBPC REINFUSION PERIOD IN HIGH DOSE TREATMENT OF NON-HODGKINS FOLLICULAR LYMPHOMA (N-HFL) WITH AND WITHOUT FILGRASTIM

    Sep 1, 2001, 00:00

  • PDG15- THE COST OF TREATING DIABETIC FOOT ULCERS (DFU) WITH APLIGRAF IN THE NETHERLANDS

    Sep 1, 2001, 00:00

  • PCN17- AN ANALYSIS OF RESOURCE USE IN THE TREATMENT OF ADVANCED COLORECTAL CANCER IN THE UK

    Sep 1, 2001, 00:00

  • PAO4- THE COST-EFFECTIVENESS OF CELECOXIB COMPARED TO DICLOFENAC IN PATIENTS WITH RHEUMATOID ARTHRITIS IN POLAND

    Sep 1, 2001, 00:00

  • PCV28- CHOLESTEROL REDUCTION SUCCESS RATES AND RESOURCE UTILIZATION BY GENDER

    Sep 1, 2001, 00:00

  • PCV8- PATIENT COMPLIANCE WITH DIFFERENT PRESCRIBED REGIMENS OF DILTIAZEM IN ANGINA PECTORIS- DATABASE ANALYSIS IN FRANCE

    Sep 1, 2001, 00:00

  • PHP6- INSURANCE CLAIMS AS A DEVICE FOR MEASURING THE PHARMACISTS SUBSTITUTION RIGHT IN A FRENCH DEPARTMENT

    Sep 1, 2001, 00:00

  • PGI13- FACTORS ASSOCIATED WITH PHYSICIAN KNOWLEDGE OF WHETHER PRESCRIPTION DRUGS ARE ON FORMULARY

    Sep 1, 2001, 00:00

  • PHP12- ACUTE CARE ELDERLY UNITS- THEIR PREVALENCE, CHARACTERISTICS AND DETERMINANTS

    Sep 1, 2001, 00:00

  • PCV17- QUALITY OF LIFE AND PATIENT PREFERENCE AS PREDICTORS FOR RESOURCE UTILIZATION AMONG PATIENTS WITH HEART FAILURE; INTERIM ANALYSIS

    Sep 1, 2001, 00:00

  • PND13- TREATMENT AND QUALITY OF LIFE AMONG PEOPLE WITH MIGRAINES

    Sep 1, 2001, 00:00

  • PIN11- A COST BENEFIT ANALYSIS OF TWO ALTERNATIVE MASS IMMUNIZATION PROGRAMS WITH A CONJUGATE VACCINE AGAINST MENINGOCCOCAL DISEASE TYPE C

    Sep 1, 2001, 00:00

  • PAR2- USE OF RESPIRATORY ASSIST DEVICES BY MEDICARE BENEFICIARIES

    Sep 1, 2001, 00:00

  • CN2- RESOURCE CONSUMPTION RELATED TO MUCOSITIS IN LYMPHOMA PATIENTS RECEIVING HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS PBPC TRANSPLANTATION

    Sep 1, 2001, 00:00

  • PCV11- COST OF WARFARIN TREATMENT OF ATRIAL FIBRILLATION IN CLINICAL PRACTICE

    Sep 1, 2001, 00:00

  • PAR9- VALIDATION OF A RATING INSTRUMENT ASSESSING THE INHALATION SKILLS OF CHILDREN WITH ASTHMA

    Sep 1, 2001, 00:00

  • PMH2- TREATMENT COURSE AND CHARGES FOR DEPRESSED PATIENTS TREATED WITH SERTRALINE, VENLAFAXINE, AND VENLAFAXINE XR IN THE MANAGED CARE SETTING

    Sep 1, 2001, 00:00

  • Mathematical Models for Formulary Committees

    Sep 1, 2001, 00:00

  • PCN25- A QUALITY OF LIFE AUDIT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER HAVING CHEMOTHERAPY AT ONE INSTITUTION

    Sep 1, 2001, 00:00

  • PDG11- HEALTH AND ECONOMIC OUTCOMES OF A NEW ORAL DIABETES DRUG, PIOGLITAZONE (ACTOSNF, TAKEDA), IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS IN NORWAY

    Sep 1, 2001, 00:00

  • PKU2- AN ECONOMIC MODEL OF UNSTABLE BLADDER IN ITALY

    Sep 1, 2001, 00:00

  • PAM16- COST IMPACT OF COX-2 INHIBITORS IN A MANAGED CARE PLAN- IMPLICATIONS FOR FORMULARY DECISION-MAKING

    Sep 1, 2001, 00:00

  • PQP3- DEFINING CLINICALLY MEANINGFUL CHANGE IN HEALTH-RELATED QUALITY OF LIFE

    Sep 1, 2001, 00:00

  • PCV31- CLOSURE OF ATRIAL SEPTAL DEFECT- MEDICO-ECONOMIC ARGUMENTS TO CHOOSE BETWEEN INVASIVE SURGERY AND PERCUTANEOUS TECHNIQUE USING SEPTAL OCCLUDER

    Sep 1, 2001, 00:00

  • PCV16- COST-EFFECTIVENESS OF AMLODIPINE TREATMENT IN PATIENTS WITH CORONARY ARTERY DISEASE IN THE U.K

    Sep 1, 2001, 00:00

  • PND8- IMPLICATIONS OF PRESCRIBING FOR PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)- INTRODUCING A TREATMENT ALGORITHM FOR GLATIRAMER ACETATE (COPAXONE)

    Sep 1, 2001, 00:00

  • PHP14- THE CURRENT STATUS AND FUTURE PROSPECTS FOR PHARMACOECONOMICS IN GREECE

    Sep 1, 2001, 00:00

  • PPN7- A MODEL FOR PREDICTING THE INCIDENCE OF MIGRAINE IN THE IDAHO MEDICAID POPULATION

    Sep 1, 2001, 00:00

  • POD14- COST-EFFECTIVENESS ANALYSIS OF THE SPECTRON VERSUS CHARNLEY HIP PROSTHESES

    Sep 1, 2001, 00:00

  • PHP12- BARRIERS THAT PREVENT THE USE OF ECONOMIC EVALUATIONS IN HOSPITAL FORMULARY DECISION-MAKING

    Sep 1, 2001, 00:00

  • PHP8- THE USE OF ECONOMIC INFORMATION IN HOSPITAL FORMULARY DEVELOPMENT IN A FRENCH REGION

    Sep 1, 2001, 00:00

  • POD6- ECONOMIC EVALUATION OF TREATING ERECTILE DYSFUNCTION IN SPAIN- THE PRIMARY CARE APPROACH VERSUS SPECIALIZED CARE

    Sep 1, 2001, 00:00

  • MH1- THE IMPACT OF SECOND-GENERATION ANTIPSYCHOTIC MEDICATIONS ON AMBULATORY PATIENTS WITH SCHIZOPHRENIA

    Sep 1, 2001, 00:00

  • PAR1- COST OF ASTHMA IN CHILDREN IN VLADIVOSTOK

    Sep 1, 2001, 00:00

  • HP1- ETHNIC DISPARITY OF COMBINATION RIBAVIRIN/INTERFERON ALFA-2B PRESCRIBING AMONG HEPATITIS C-INFECTED MEMBERS IN A MANAGED CARE ORGANIZATION (MCO)

    Sep 1, 2001, 00:00

  • PRP13- IMPACT OF ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS (AECB) IN FRANCE

    Sep 1, 2001, 00:00

  • PDG1- THE OUTCOMES OF LONG-TERM TREATMENT OF A NEW ORAL DIABETES DRUG PIOGLITAZONE (ACTOS ) IN THE MANAGEMENT OF TYPE 2 DIABETES IN FINLAND

    Sep 1, 2001, 00:00

  • PGI5- HEALTH CARE COST SAVINGS WITH BUDESONIDE CONTROLLED ILEAL RELEASE CAPSULES (CIR) IN CROHNS DISEASE

    Sep 1, 2001, 00:00

  • PMH9- HEALTH CARE UTILIZATION AND COSTS IN SCHIZOPHRENIC PATIENTS TAKING RISPERIDONE VERSUS OLANZAPINE IN A VETERANS ADMINISTRATION POPULATION

    Sep 1, 2001, 00:00

  • PMA6- THE REDUCTION OF SAMPLE SIZE FOR A COST-EFFECTIVENESS TRIAL USING A NEW METHOD- THE EIGHT CASES IN JAPAN

    Sep 1, 2001, 00:00

  • PND9- IMPACT OF RIVASTIGMINE ON ANTIPSYCHOTIC UTILIZATION AND COST IN ALZHEIMERS DISEASE

    Sep 1, 2001, 00:00

  • MD4- INCLUSION OF INDIRECT COST IN ECONOMIC OUTCOMES ANALYSES OF MEDICAL DEVICES- HOW IMPORTANT IS IT?

    Sep 1, 2001, 00:00

  • PMH13- THE DIRECT COST OF RISPERIDONE VERSUS HALOPERIDOL THERAPY FOR CHRONIC SCHIZOPHRENIA IN POLAND

    Sep 1, 2001, 00:00

  • PID21- THE COST-EFFECTIVENESS ANALYSIS OF LAMIVUDINE IN THE TREATMENT OF CHRONIC HEPATITIS B IN POLAND

    Sep 1, 2001, 00:00

  • PID1- EFFICACY OF ZINC LOZENGES ON THE DURATION OF COMMON COLD SYMPTOMS- A META-ANALYSIS REVISITED

    Sep 1, 2001, 00:00

  • PAM13- A COST-EFFECTIVENESS MODEL COMPARING CELECOXIB AND ROFECOXIB TO TRADITIONAL NSAIDS FOR OSTEOARTHRITIS TREATMENT

    Sep 1, 2001, 00:00

  • PPN11- THE MIGRAINE IN FRANCE IN 2000- EPIDEMIOLOGICAL DATA

    Sep 1, 2001, 00:00

  • PDG25- ECONOMIC DIFFERENTIATION BETWEEN PPIS IN THE TREATMENT OF REFLUX ESOPHAGITIS RELATED TO GERD

    Sep 1, 2001, 00:00

  • PAM6- COST-EFFECTIVENESS OF ROFECOXIB VERSUS NSAIDS IN THE TREATMENT OF OSTEOARTHRITIS

    Sep 1, 2001, 00:00

  • EM4- CAN UNIT COSTS BE COMPARED ACROSS WESTERN EUROPEAN COUNTRIES?

    Sep 1, 2001, 00:00

  • PMI26- ASSESSMENT OF RESPONDENT ACCEPTABILITY OF UTILITY MEASURES- DISCRIMINATORY POWER OF GRAPHIC POSITIONING SCALE VERSUS TRADITIONAL SCALING MEASURES

    Sep 1, 2001, 00:00

  • PCV28- COST-CONSEQUENCES OF LOW-MOLECULARWEIGHT HEPARIN (LMWH) COMPARED WITH HEPARIN IN UNSTABLE CORONARY ARTERY DISEASE IN JAPAN

    Sep 1, 2001, 00:00

  • PID2- IMPACT OF CYTOMEGALOVIRUS (CMV)-RELATED READMISSION ON POST HEART TRANSPLANT RESOURCE USE

    Sep 1, 2001, 00:00

  • PCV8- COST-EFFECTIVENESS OF CLOPIDOGREL COMPARED WITH TICLOPIDINE IN THROMBOSIS PREVENTION- DECISION ANALYSIS TAKING INTO ACCOUNT SIDE-EFFECTS

    Sep 1, 2001, 00:00

  • MS3- CORRELATION OF A GENERIC HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE AND SELF-ADMINISTERED RHEUMATOID ARTHRITIS DISEASE ACTIVITY INSTRUMENT

    Sep 1, 2001, 00:00

  • PHP9- THE INFLUENCE OF UPDATING THE ISRAELI NATIONAL DRUG LIST ON AVERAGE NUMBER OF DRUGS PRESCRIBED TO A PATIENT

    Sep 1, 2001, 00:00

  • PUR1- HEALTH STATUS OF ELDERLY DIALYSIS PATIENTS

    Sep 1, 2001, 00:00

  • PAM21- MANUAL THERAPY IS MORE COST-EFFECTIVE THAN PHYSICAL THERAPY AND GP CARE FOR PATIENTS WITH NECK PAIN

    Sep 1, 2001, 00:00

  • PCN16- CHEMOTHERAPY TREATMENT IN NEWLY DIAGNOSED BREAST CANCER PATIENTS IN A MANAGED CARE POPULATION

    Sep 1, 2001, 00:00

  • PMH15- A RETROSPECTIVE ECONOMIC EVALUATION OF OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA

    Sep 1, 2001, 00:00

  • PID24- COST COMPARISON OF GATIFLOXACIN VERSUS LEVOFLOXACIN IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN AN OUTPATIENT POPULATION

    Sep 1, 2001, 00:00

  • PMA10- DESCRIPTION OF COST/EFFECTIVENESS RATIO DISTRIBUTIONS

    Sep 1, 2001, 00:00

  • PMH17- TYPICAL AND ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA- ASSESSMENT OF CLINICAL AND ECONOMIC OUTCOMES USING A MARKOV MODEL

    Sep 1, 2001, 00:00

  • PCV20- COST-EFFECTIVENESS STUDY TO DETERMINE THE IMPACT OF A TOBACCO OUTREACH PROGRAM FOR ADOLESCENTS

    Sep 1, 2001, 00:00

  • PMH11- SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM (SCAP)- THE IMPACT OF CLINICAL SYNDROME, ANTIPSYCHOTIC MEDICATION TREATMENT AND ADHERENCE ON OUTPATIENT PSYCHIATRIC UTILIZATION

    Sep 1, 2001, 00:00

  • PAR17- PATIENT SATISFACTION WITH NON-SEDATING ANTIHISTAMINES

    Sep 1, 2001, 00:00

  • PND2- COMPARISON OF ADVERSE REACTION REPORTS FOR RIVASTIGMINE AND DONEPEZIL USING THE FDAS ADVERSE EVENT REPORTING SYSTEM

    Sep 1, 2001, 00:00

  • IN2- THE ECONOMIC BURDEN OF VIRAL RESPIRATORY INFECTION IN THE UNITED STATES

    Sep 1, 2001, 00:00

  • PCN20- COST MINIMIZATION ANALYSIS OF CEFEPIME VERSUS IMIPENEM-CILASTATINE IN CANCER PATIENTS WITH SHORT-DURATION FEBRILE NEUTROPENIA

    Sep 1, 2001, 00:00

  • PCV4- ASSESSING THE IMPACT OF HYPERLIPIDEMIA TREATMENT WITH PRAVASTATIN AND SIMVASTATIN IN A LARGE COUNTY INSTITUTION

    Sep 1, 2001, 00:00

  • PCV3- ENOXAPARIN - A PHARMACOECONOMIC REVIEW OF ITS USE IN THROMBOEMBOLIC PROPHYLAXIS

    Sep 1, 2001, 00:00

  • PMH3- PATIENT MEDICATION ATTITUDE AFTER SWITCHING TOZIPRASIDONE FROM OTHER ANTIPSYCHOTICS

    Sep 1, 2001, 00:00

  • PAR18- COSTS OF TREATING COPD IN ITALY- A BURDEN OF ILLNESS STUDY

    Sep 1, 2001, 00:00

  • CN1- BRIEF ASSESSMENT OF PRIORITY SYMPTOMS IN HORMONE REFRACTORY PROSTATE CANCER (HRPCA)

    Sep 1, 2001, 00:00

  • PMH5- FROM FIRST TO SECOND- IMPACT OF PARTICIPANT CHARACTERISTICS ON THE TIME TO FIRST SWITCH IN A SCHIZOPHRENIA POPULATION

    Sep 1, 2001, 00:00

  • QL3- QUALITY OF LIFE IN PRODUCT LABELING- A REVIEW OF MARKETED DRUG PRODUCTS

    Sep 1, 2001, 00:00

  • PCV29- PERSISTENCY OF TREATMENT IN PATIENTS INITIATED ON FIVE DIFFERENT CLASSES OF ANTIHYPERTENSIVE THERAPY- A PHARMACO-UTILIZATION AND PHARMACO-ECONOMIC ANALYSIS

    Sep 1, 2001, 00:00

  • PMH10- HEALTH OUTCOMES OF CHILDHOOD ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)- HEALTH CARE USE AND WORK STATUS OF CAREGIVERS

    Sep 1, 2001, 00:00

  • CN1- UTILITIES OF METASTATIC BREAST CANCER PATIENTS (PT) TREATED WITH TAXANES COMPARED TO UTILITIES OF ONCOLOGY NURSES (NUR)

    Sep 1, 2001, 00:00

  • PCN28- DETECTING RECURRENT PAPILLARY OR FOLLICULAR THYROID CANCER IN CLINICALPRACTICE- NEED FOR A CHANGE?

    Sep 1, 2001, 00:00

  • MH2- EFFICACY OF NURSE TELEHEALTH CARE AND PEER SUPPORT IN AUGMENTING TREATMENT OF DEPRESSION IN PRIMARY CARE

    Sep 1, 2001, 00:00

  • PMH4- DRUG SELECTION, DOSING, AND UTILIZATION PATTERNS AMONG DEPRESSED PATIENTS TREATED WITH SSRIS AND VENLAFAXINE IN US MANAGED CARE PLANS

    Sep 1, 2001, 00:00

  • POD7- THE EF-VAS- A PREFERENCE-BASED SELFADMINISTRATION INSTRUMENT FOR ASSESSING THE IMPACT OF ERECTILE DYSFUNCTION (ED) AND ED TREATMENT

    Sep 1, 2001, 00:00

  • Management Strategies for Ribavirin-Induced Hemolytic Anemia in the Treatment of Hepatitis C- Clinical and Economic Implications

    Sep 1, 2001, 00:00

  • PGI17- COMPARISON OF GENERIC VERSUS DISEASE SPECIFIC TOOLS FOR THE MEASUREMENT OF HEALTH-RELATED QUALITY OF LIFE IN CROHNS DISEASE

    Sep 1, 2001, 00:00

  • PIN13- CAN VARICELLA BE ELIMINATED BY UNIVERSAL CHILDHOOD VACCINATION COST-BENEFICIALLY? EXAMPLES FOR EUROPE

    Sep 1, 2001, 00:00

  • Impact of Long-Term Complications on Quality of Life in Patients with Type 2 Diabetes not Using Insulin

    Sep 1, 2001, 00:00

  • MD1- COST-EFFECTIVENESS OF AIRLINE DEFIBRILLATORS- IS PEACE OF MIND MORE IMPORTANT THAN SAVING LIVES?

    Sep 1, 2001, 00:00

  • PRP12- ASTHMA KNOWLEDGE AND QUALITY OF LIFE (QOL) OF ADULT ASTHMATICS

    Sep 1, 2001, 00:00

  • PIN12- BURDEN OF ILLNESS IMPOSED BY SEVERE SEPSIS IN GERMANY

    Sep 1, 2001, 00:00

  • PND7- ESTIMATION OF THE COSTS OF MULTIPLE SCLEROSIS BASED ON 157 FRENCH PATIENTS

    Sep 1, 2001, 00:00

  • PMA16- CONFIRMATION OF THE DECISION RULES AND ASSUMPTIONS FOR A MODEL OF DIABETES TREATMENT USING AN EXPERT PANEL

    Sep 1, 2001, 00:00

  • PDG14- AN ASSESSMENT OF THE COSTEFFECTIVENESS OF PIOGLITAZONE (ACTOSNF, TAKEDA) IN TYPE 2 DIABETES MELLITUS IN DENMARK

    Sep 1, 2001, 00:00

  • QL2- ESTIMATING PATIENTS PREFERENCES IN TREATMENT CHOICES INVOLVING RISK- A NEW MODIFIED STANDARD GAMBLE METHOD

    Sep 1, 2001, 00:00

  • PGI10- IRRITABLE BOWEL SYNDROME COSTS SICKNESS FUNDS DM 2.8 BILLION PER YEAR

    Sep 1, 2001, 00:00

  • PIN7- PHARMACOECONOMIC EVALUATION OF IMIQUIMOD (ALDARA) FOR THE TREATMENT OF EXTERNAL GENITAL WARTS IN A DUTCH TREATMENT ENVIRONMENT

    Sep 1, 2001, 00:00

  • WW13- CHALLENGES IN PERFORMING META ANALYSIS IN HEART FAILURE OUTCOMES RESEARCH

    Sep 1, 2001, 00:00

  • PGI11- CHARACTERIZATION AND MARKOV MODELING OF GASTROESOPHAGEAL REFLUX DISEASE STATES IN A LARGE HEALTH CARE PLAN

    Sep 1, 2001, 00:00

  • PRP11- EFFECTS OF DISEASE MANAGEMENT ON QUALITY OF LIFE IN PATIENTS WITH ASTHMA

    Sep 1, 2001, 00:00

  • PIN21- ANTIBIOTIC PROPHYLAXIS IN TOTAL HIP REPLACEMENT SURGERY- ASSESSMENT OF GLOBAL CONFORMITY TO FRENCH GUIDELINES

    Sep 1, 2001, 00:00

  • PIN5- COST-UTILITY ANALYSIS OF A PNEUMOCOCCAL/MENINGOCOCCAL COMBINATION VACCINE FOR INFANTS

    Sep 1, 2001, 00:00

  • DS3- DESIGN AND ANALYSIS OF UNIT COST ESTIMATION STUDIES- HOW MANY TYPES OF HOSPITALIZATION? HOW MANY COUNTRIES?

    Sep 1, 2001, 00:00

  • PUR2- EVIDENCE OF DISEASE PROGRESSION IN ADULT PATIENTS WITH AN OVERACTIVE BLADDER (OAB)

    Sep 1, 2001, 00:00

  • DS2- POWER CALCULATIONS FOR WIDELY USED PATIENT-REPORTED OUTCOMES (PRO) MEASURES IN WOMENS HEALTH TRIALS

    Sep 1, 2001, 00:00

  • PHP16- THE VALUE OF VARIOUS FORMS OF EVIDENCE IN DRUG FORMULARY DECISION MAKING

    Sep 1, 2001, 00:00

  • PMI6- ESTIMATING AND COMPARING RESOURCE USE AND COST OF G-CSF USE IN CHEMOTHERAPY WITH THE ACTIVITY-BASED COSTING (ABC) METHOD IN THREE SETTINGS

    Sep 1, 2001, 00:00

  • PUR4- ANALYSIS OF COMORBIDITY IN OVERACTIVE BLADDER AND URINARY INCONTINENCE IN A MANAGED CARE ORGANIZATION

    Sep 1, 2001, 00:00

  • PHP5- POLISH GUIDELINES FOR CONDUCTING PHARMACOECONOMIC EVALUATIONS IN COMPARISON TO INTERNATIONAL HEALTH ECONOMIC GUIDELINES

    Sep 1, 2001, 00:00

  • PAR6- PROPHYLACTIC MEDICATION UTILIZATION AND HEALTH CARE COSTS IN OLDER ADULTS WITH CHRONIC PULMONARY AILMENTS

    Sep 1, 2001, 00:00

  • PCN22- COST-EFFECTIVENESS ANALYSIS COMPARING PACLITAXEL TO DOCETAXEL IN THE TREATMENT OF METASTATIC BREAST CANCER

    Sep 1, 2001, 00:00

  • PHP15- IMPACT OF FIRST GENERIC ENTRANTS ON BRAND NAME PRODUCTS

    Sep 1, 2001, 00:00

  • PID4- ECONOMIC COST OF HIV INFECTION IN UNTREATED WORKERS- AN EMPLOYERS PERSPECTIVE

    Sep 1, 2001, 00:00

  • PCN12- THE RELATIONSHIP OF AGE AND DURATION OF HORMONAL THERAPY USE AMONG PATIENTS DIAGNOSED WITH CANCER OF THE PROSTATE

    Sep 1, 2001, 00:00

  • PMI8- DO HEALTH CARE PURCHASERS PREFER PAYING FOR LIFE EXTENSION OR QUALITY OF LIFE IMPROVEMENT?

    Sep 1, 2001, 00:00

  • PIN17- HOW CAN PRODUCTS WITH MARGINAL EFFICACY SAVE MONEY? THE EXAMPLE OF A NON SPECIFIC, IMMUNOSTIMULATING, PREVENTIVE TREATMENT FOR RECURRENT UPPER RESPIRATORY TRACT INFECTIONS IN CHILDREN

    Sep 1, 2001, 00:00

  • PGI1- EFFECTS ON HEALTH CARE CONTACTS AND DAYS ABSENT FROM WORK WITH BUDESONIDE CIR CAPSULES IN THE MAINTENANCE TREATMENT OF CROHNS DISEASE IN A US SETTING

    Sep 1, 2001, 00:00

  • PHP1- THE ECONOMICS OF PARALLEL TRADE IN PHARMACEUTICALS- EXPERIENCES FROM SWEDEN

    Sep 1, 2001, 00:00

  • PCV15- ECONOMIC EVALUATION OF OUTPATIENT ANTICOAGULANT/ANTIPLATELET THERAPY FOLLOWING CORONARY STENTING IN A MANAGED CARE POPULATION

    Sep 1, 2001, 00:00

  • PCV10- A PHARMACOECONOMIC ANALYSIS OF PATIENT OUTCOMES IN THE CORONARY ANGIOPLASTY AMLODIPINE RESTENOSIS STUDY (CAPARES) IN NORWAY AND CANADA

    Sep 1, 2001, 00:00

  • RP2- THE NET COST OF ASTHMA TO A US PUBLIC MEDICAID PROGRAM

    Sep 1, 2001, 00:00

  • PDB2- USING RETROSPECTIVE CLAIMS DATA TO DESIGN CLINICAL SAFETY SURVEILLANCE OF THIAZOLIDINEDIONE DRUGS

    Sep 1, 2001, 00:00

  • PMA9- BAYESIAN OR CLASSICAL DESIGN AND ANALYSIS- DOES IT MAKE A DIFFERENCE??

    Sep 1, 2001, 00:00

  • PCV31- A DECISION-ANALYSIS MODEL FOR ENHANCING MEDICATION ADHERENCE IN PATIENTS TAKING STATINS

    Sep 1, 2001, 00:00

  • PCV39- COST OF TREATMENT OF HYPERCHOLESTEROLAEMIA TO NHF GOALS IN AUSTRALIA

    Sep 1, 2001, 00:00

  • PCV37- THE COST-EFFECTIVENESS OF STATINS- EVIDENCE FROM THE ACCESS TRIAL

    Sep 1, 2001, 00:00

  • PDG9- THE EVENT AND STATE COST OF COMPLICATIONS OF DIABETES IN THE NETHERLANDS

    Sep 1, 2001, 00:00

  • PDG12- CLINICAL BENEFITS AND COST-OFFSETS OF COMBINATION THERAPY WITH NATEGLINIDE PLUS METFORMIN VERSUS METFORMIN ALONE IN DIABETES IN THE NETHERLANDS

    Sep 1, 2001, 00:00

  • HP2- THE ROLE OF OUTLIER PAYMENTS IN MEDICARE PATIENTS WITH SEVERE SEPSIS

    Sep 1, 2001, 00:00

  • PWM6- COST-EFFECTIVENESS OF INTRAVAGINAL PROSTAGLANDIN E2 GEL AND INTRAVAGINAL MISOPROSTOL FOR PREINDUCTION CERVICAL RIPENING

    Sep 1, 2001, 00:00

  • PHP2- ATTITUDE OF PHYSICIANS TOWARD FORMULARIES AND SERVICES PROVIDED BY PHARMACIST

    Sep 1, 2001, 00:00

  • PCV2- COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL COMPARED WITH TICLOPIDINE IN THROMBOSIS PREVENTION

    Sep 1, 2001, 00:00

  • PGI3- A PROSPECTIVE, RANDOMIZED COST ANALYSIS OF MEPERIDINE AND MIDAZOLAM VERSUS PROPOFOL FOR COMPLEX UPPER ENDOSCOPY PROCEDURES

    Sep 1, 2001, 00:00

  • PRP6- ASMACARE STUDY. ASSESSMENT OF THE IMPACT OF AN INTERVENTION DESIGNED TO IMPROVE THE MANAGEMENT OF ASTHMA PATIENTS

    Sep 1, 2001, 00:00

  • PND10- CONCOMITANT DRUG USE IMPLICATIONS IN ALZEIMERS DISEASE PATIENTS USING DONEPEZIL

    Sep 1, 2001, 00:00

  • PAO10- PSYCHOMETRIC VALIDATION OF THE ARTHRITIS TREATMENT SATISFACTION QUESTIONNAIRE (ARTS)

    Sep 1, 2001, 00:00

  • PKU5- HEALTH-RELATED CONSEQUENCES AND COSTS OF OVERACTIVE BLADDER

    Sep 1, 2001, 00:00

  • PMI10- THE NICE' APPROACH TO PHARMACOECONOMICS- AN ECONOMICS PERSPECTIVE

    Sep 1, 2001, 00:00

  • DG4- DISEASE SEVERITY DETERMINES COST OF GASTROESOPHAGEAL REFLUX DISEASE IN A MIDWEST USA HEALTH CARE PLAN

    Sep 1, 2001, 00:00

  • PEE9- THE SOCIETAL COST OF ATOPIC DERMATITIS IN GERMANY

    Sep 1, 2001, 00:00

  • PEE2- THE COST-EFFECTIVENESS OF GENETIC TESTING FOR PERIODONTAL DISEASE. A PAYERS PERSPECTIVE

    Sep 1, 2001, 00:00

  • PMI22- MICE (MODULE FOR STANDARDISED INDIRECT COST ESTIMATION) INCREASES THE TRANSFERABILITE OF STUDY RESULTS

    Sep 1, 2001, 00:00

  • PHP22- PERCEIVED QUALITY OF LIFE AND MEDICINE CONSUMPTION IN ELDERLY OUTPATIENTS

    Sep 1, 2001, 00:00

  • PPN12- DIFFERENCES IN HEALTH-RELATED QUALITY OF LIFE BETWEEN MIGRAINEURS WITH AND WITHOUT PROPHYLACTIC MEDICATION USE

    Sep 1, 2001, 00:00

  • PDG8- A POPULATION STUDY OF HEALTH-CARE COSTS ASSOCIATED WITH HYPOGLYCAEMIA

    Sep 1, 2001, 00:00

  • PPN5- COMPARISON OF COSTS AND COST-EFFECTIVENESS OF OXCARBAZEPINE AND SODIUM VALPROATE FOR NEW/RECENT ONSET PARTIAL SEIZURES

    Sep 1, 2001, 00:00

  • PAM1- JOINT COUNTS IN PATIENTS WITH NEW ONSET RHEUMATOID ARTHRITIS- PATIENT VS. PHYSICIAN ASSESSMENT

    Sep 1, 2001, 00:00

  • MH3- RECENT WEIGHT GAIN AND THE COST OF ACUTE SERVICE USE AMONG INDIVIDUALS WITH SCHIZOPHRENIA

    Sep 1, 2001, 00:00

  • PPN18- COST SAVINGS IN MIGRAINE ASSOCIATED WITH LESS CHEST PAIN ON NEW TRIPTAN THERAPY

    Sep 1, 2001, 00:00

  • PRP4- COST-CONSEQUENCE ANALYSIS OF TIOTROPIUM VERSUS IPRATROPIUM FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    Sep 1, 2001, 00:00

  • PEE11- PSORIASIS AND EVERYDAY LIFE- FIRST RESULTS

    Sep 1, 2001, 00:00

  • PRP14- ASSESSING PATIENTS PREFERENCES FOR CONVENTIONAL AND HOMEOPATHIC TREATMENT FOR ASTHMA-A CONJOINT ANALYSIS STUDY

    Sep 1, 2001, 00:00

  • PCV19- DISCRIMINABILITY FOR RISK OF CARDIOVASCULAR EVENTS

    Sep 1, 2001, 00:00

  • PUR7- CLINICAL CORRELATES WITH HEALTH-RELATED QUALITY OF LIFE SCORES AND SUBSCALES AMONG CONSULTING AND NON-CONSULTING INDIVIDUALS WITH STRESS URINARY INCONTINENCE

    Sep 1, 2001, 00:00

  • PID20- TARGETING POPULATIONS AT-RISK FOR URINARY TRACT INFECTION COMPLICATION

    Sep 1, 2001, 00:00

  • PRP3- SPECIFIC IMMUNOTROPIC THERAPY - ASPECTS OF COST-EFFECTIVENESS

    Sep 1, 2001, 00:00

  • PMH19- IDENTIFICATION AND ONE-YEAR COSTS OF TREATMENT-RESISTANT DEPRESSION IN A CLAIMS DATA ANALYSIS

    Sep 1, 2001, 00:00

  • QL2- LOGICAL CONSISTENCY AND THE VALUATION OF HEALTH- AN ANALYSIS OF US SURVEY DATA

    Sep 1, 2001, 00:00

  • PMI20- A REAL OPTION APPROACH TO VALUING PHARMACEUTICAL INVESTMENTS AND FIRMS

    Sep 1, 2001, 00:00

  • PMI21- ESTIMATING INFLUENZA-RELATED EXCESS HOSPITAL ADMISSIONS

    Sep 1, 2001, 00:00

  • PEE6- COST-EFFECTIVENESS OF ARTIFICIAL SKIN SUBSTITUTE VS ALLOGRAFT FOR BURN PATIENTS

    Sep 1, 2001, 00:00

  • PAM20- COST-EFFECTIVENESS OF ACETYLCISTEINE AND DIMETHYLSULPHOXIDE (DMSO) 50 FOR THE TREATMENT OF PATIENTS WITH REFLEX SYMPATHIC DYSTROPHY

    Sep 1, 2001, 00:00

  • WW17- SELECTING HEALTH-RELATED QUALITY-OF-LIFE MEASURES- FIRST PRINCIPLES

    Sep 1, 2001, 00:00

  • RS4- A MODEL-BASED EVALUATION OF INHALED STEROIDS IN MILD-TO-MODERATE ASTHMA

    Sep 1, 2001, 00:00

  • PEE2- COSTS AND CONSEQUENCES OF OLOPATADINE 0.1 IN THE TREATMENT OF SEASONAL ALLERGIC CONJUNCTIVITIS

    Sep 1, 2001, 00:00

  • PAO8- THE COST-EFFECTIVENESS OF INFLIXIMAB FOR SEVERE RHEUMATOID ARTHRITIS

    Sep 1, 2001, 00:00

  • PUR8- THE INFLUENCE OF RACE ON SF-36 SCORES OF DIALYSIS PATIENTS

    Sep 1, 2001, 00:00

  • PHP15- A SURVEY OF PUBLIC HOSPITAL PHARMACISTS IN SINGAPORE ON THEIR VIEWS ABOUT THE FORMULARY' AND ITS DECISION-MAKING PROCESS

    Sep 1, 2001, 00:00

  • PMH18 HEALTH CARE UTILIZATION IN PATIENTS WITH TREATMENT RESISTANT DEPRESSION

    Sep 1, 2001, 00:00

  • PIN20- ESTIMATING THE RETURN ON INVESTMENT FOR TUBERCULOSIS DRUGS

    Sep 1, 2001, 00:00

  • PID22- AN APPRAISAL OF HEALTH-RELATED QUALITY OF LIFE INSTRUMENTS FOR USE IN PATIENTS DIAGNOSED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE

    Sep 1, 2001, 00:00

  • PDB5- A COST-MINIMIZATION STUDY TO DETERMINE THE IMPACT OF ADDING GLUCOVANCE TO A COUNTY HOSPITAL FORMULARY

    Sep 1, 2001, 00:00

  • QL1- CAN HEALTH STATE VALUES BE PREDICTED FROM HEALTH-RELATED QUALITY OF LIFE MEASURES?

    Sep 1, 2001, 00:00

  • PCN5- FIRST-LINE THERAPY FOR ADVANCED BREAST CANCER - COST-EFFECTIVENESS OF ANASTROZOLE VERSUS TAMOXIFEN

    Sep 1, 2001, 00:00

  • PCN18- COLORECTAL CANCER SCREENING- AWARENESS, UTILIZATION, AND BARRIERS

    Sep 1, 2001, 00:00

  • PDB15- DOES PATIENT EXPERIENCE MATTER? TYPE II DIABETES PATIENTS STATED PREFERENCES FOR INSULIN THERAPIES

    Sep 1, 2001, 00:00

  • PRP2 ASTHMA MANAGEMENT AND OUTCOMES IN ITALY

    Sep 1, 2001, 00:00

  • PWM5- HEALTH CARE USE ATTRIBUTABLE TO PROSTATE NON-SELECTIVE ALPHA-1 ANTAGONIST INITIATION FOR BENIGN PROSTATIC HYPERPLASIA (BPH)

    Sep 1, 2001, 00:00

  • PMH6- PATTERNS OF COMORBIDITIES AND COPRESCRIBING AMONG DEPRESSED PATIENTS TREATED WITH SSRIS AND VENLAFAXINE IN US MANAGED CARE PLANS

    Sep 1, 2001, 00:00

  • PDG23- PHARMACEUTICAL AND HOSPITAL EXPENDITURE FOR ANTI-DYSPEPTIC TREATMENT- THE EFFECTS OF THE INTRODUCTION OF A DISEASE MANAGEMENT GUIDELINE

    Sep 1, 2001, 00:00

  • PCN19- COLORECTAL CANCER SCREENING TESTS- VARIATION IN PREFERENCES BASED ON GENDER AND RACE

    Sep 1, 2001, 00:00

  • IN3- THE OBSERVED COSTS AND HEALTH-CARE USE OF CHILDREN IN A RANDOMIZED CONTROLLED TRIAL OF PNEUMOCOCCAL CONJUGATE VACCINE

    Sep 1, 2001, 00:00

  • ID3- COST-EFFECTIVENESS ANALYSIS OF AN INTRANASAL INFLUENZA VACCINE FOR HEALTHY CHILDREN

    Sep 1, 2001, 00:00

  • PIN2- COST-EFFECTIVENESS OF HIV-SCREENING OF PATIENTS ATTENDING A CLINIC FOR SEXUALLY TRANSMITTED DISEASES IN AMSTERDAM

    Sep 1, 2001, 00:00

  • PMA5- A RISK ADJUSTMENT METHODOLOGY FOR CLAIMS DATA

    Sep 1, 2001, 00:00

  • PCV35- STOP SMOKING CESSATION TARGET- OBSERVATION PROGRAM AN EX-SMOKER IS A SMOKER IN PROGRESSION

    Sep 1, 2001, 00:00

  • ID1- DEVELOPMENT OF A STOCHASTIC DECISION ANALYSIS MODEL OF TREATMENT OF PYELONEPHRITIS FROM THE RESULTS OF AN RCT

    Sep 1, 2001, 00:00

  • PCV32- STRATEGIES FOR IMPROVING COMPLIANCE WITH HMG-COA REDUCTASE INHIBITORS

    Sep 1, 2001, 00:00

  • PCV24- COSTS OF HYPERTENSION IN POLAND

    Sep 1, 2001, 00:00

  • DG1- THE RELATIONSHIP OF DIABETES SYMPTOMS AND HEALTH-RELATED QUALITY OF LIFE

    Sep 1, 2001, 00:00

  • PID26- PHARMACOECONOMIC EVALUATION OF CEFUROXIME IN ABDOMINAL HYSTERECTOMY

    Sep 1, 2001, 00:00

  • PCV7- COST-UTILITY ANALYSIS OF DRUG THERAPY OPTIONS FOR INTERMITTENT CLAUDICATION

    Sep 1, 2001, 00:00

  • PID17 ECONOMIC EVALUATION OF OSELTAMIVIR FOR INFLUENZA PATIENTS IN JAPAN

    Sep 1, 2001, 00:00

  • WW14- MAKING MODELS BETTER

    Sep 1, 2001, 00:00

  • HP2- TRANSLATING EVIDENCE TO PRACTICE IN BREAST CANCER

    Sep 1, 2001, 00:00

  • PID15- MANAGING AIDS IN THE ERA OF ANTIRETROVIRAL THERAPY- CHANGES IN THE RATE AND COST OF HOSPITALIZATIONS

    Sep 1, 2001, 00:00

  • WW11- USING MARKOV DECISION MODELS TO DEVELOP OPTIMAL TREATMENT PATHWAYS- AN ILLUSTRATION

    Sep 1, 2001, 00:00

  • CE3- THE COST OF UPPER GASTRODUODENAL ENDOSCOPY- AN ACTIVITY-BASED APPROACH

    Sep 1, 2001, 00:00

  • PND11- DISEASE MANAGEMENT IN MIGRAINE AND TENSION-TYPE HEADACHE - RESULTS OF A SOCIO-ECONOMIC PILOT STUDY

    Sep 1, 2001, 00:00

  • The Impact of Risk on Preference Values- Implications for Evaluations of Postmenopausal Osteoporosis Therapy

    Sep 1, 2001, 00:00

  • PID23- PATTERNS OF ANTIBIOTIC USE AND COSTS ASSOCIATED WITH EPISODES OF TREATMENT FOR COMMON OUTPATIENT RESPIRATORY-TRACT INFECTIONS- AN ANALYSIS OF MANAGED-CARE DATA

    Sep 1, 2001, 00:00

  • PPN13- DELAYS IN NURSING HOME PLACEMENT FOR PATIENTS WITH ALZHEIMERS DISEASE ASSOCIATED WITH TREATMENT WITH DONEPEZIL MAY HAVE HEALTH CARE COST-SAVING IMPLICATIONS

    Sep 1, 2001, 00:00

  • PAR4- COMPARISON OF TWO QUALITY OF LIFE INSTRUMENTS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    Sep 1, 2001, 00:00

  • WW10- MULTINATIONAL ECONOMIC STUDIES- LESSONS LEARNED FROM TRIAL-BASED AND MODELLING STUDIES

    Sep 1, 2001, 00:00

  • PMH10- MANAGEMENT AND COST OF A MANIC EPISODE IN BIPOLAR DISORDER-A FRENCH STUDY

    Sep 1, 2001, 00:00

  • PND5- THE COST OF SECONDARY STROKE IN POLAND

    Sep 1, 2001, 00:00

  • PMH7- CHANGE IN MALADAPTIVE BEHAVIORS ASSOCIATED WITH ANTIDEPRESSANTS IN OLDER DEPRESSED PATIENTS

    Sep 1, 2001, 00:00

  • PGI14- HOW IMPORTANT IS APPROPRIATE EMPIRICAL ANTIBIOTIC TREATMENT FOR INTRA-ABDOMINAL INFECTIONS?

    Sep 1, 2001, 00:00

  • PRP5- ESTIMATES OF LOST PRODUCTIVE WORK TIME ASSOCIATED WITH ALLERGIC RHINITIS (AR)

    Sep 1, 2001, 00:00

  • PCN9- ECONOMIC EVALUATION OF GEMZAR/CISPLATIN RELATIVE TO OTHER NEW AGENTS FOR NON SMALL CELL LUNG CANCER (NSCLC) IN THE UK

    Sep 1, 2001, 00:00

  • PCV3- AN ANALYSIS OF THE COST OF ADVERSE EVENTS ASSOCIATED WITH THE USE OF HMG-COA REDUCTASE INHIBITORS

    Sep 1, 2001, 00:00

  • CV3- DO SHORT-ACTING OPIATES IN OFF-PUMP BYPASS SURGERY REDUCE LENGTH OF STAY OR TOTAL HOSPITAL COSTS?

    Sep 1, 2001, 00:00

  • PKU6- INTERNATIONAL PSYCHOMETRIC VALIDATION AND CROSS-CULTURAL EQUIVALENCE OF A URINARY INCONTINENCE SPECIFIC QOL SCALE (CONTILIFE) IN SIX EUROPEAN COUNTRIES

    Sep 1, 2001, 00:00

  • PHP13- INDICES FOR EVALUATION OF DRUG COST/UTILIZATION- EVERY SILVER LINING HAS A GRAY CLOUD

    Sep 1, 2001, 00:00

  • PHP6- ACTIVITIES, FUNCTIONS AND STRUCTURE OF PHARMACY AND THERAPEUTICS COMMITTEES IN ISRAELI HOSPITALS

    Sep 1, 2001, 00:00

  • WW15- IDENTIFYING THE IMPACT OF A TREATMENT ON OUTCOMES AND COSTS USING OBSERVATIONAL DATA- OVERCOMING SELECTION BIAS

    Sep 1, 2001, 00:00

  • PAR22- IMPACT OF LEVALBUTEROL VERSUS RACEMIC ALBUTEROL ON OUTPATIENT ASTHMA CARE CHARGES

    Sep 1, 2001, 00:00

  • PHP3- MACRO-ECONOMIC ANALYSIS OF HEROIN MARKETS IN THE EU AND THE IMPACT OF SUBSTITUTION TREATMENT

    Sep 1, 2001, 00:00

  • PGI9- COST-EFFECTIVENESS OF TREAT' HELICOBACTER PYLORI INFECTED DYSPEPTIC PATIENTS IN A PRIMARY CARE SETTING

    Sep 1, 2001, 00:00

  • PCN24- INCIDENCE AND COST OF HOSPITALIZATION FOR 5-FU TOXICITY AMONG MEDICARE BENEFICIARIES WITH METASTATIC COLORECTAL CANCER

    Sep 1, 2001, 00:00

  • POD1- ESTIMATING THE SEMI-FIXED COSTS OF A DAY-CASE EPISODE

    Sep 1, 2001, 00:00

  • POD9- AN ANALYSIS OF THE USEFULNESS AND TRANSPARENCY OF COST-EFFECTIVENESS LITERATURE FOR SURGICAL DEVICES AND PROCEDURES

    Sep 1, 2001, 00:00

  • PCN26- SYSTEMATIC ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE INSTRUMENTS FOR USE IN CLINICAL TRIALS OF NON-SMALL CELL LUNG CANCER

    Sep 1, 2001, 00:00

  • PMH31- PHARMACOECONOMIC EVALUATION OF THE TREATMENT WITH OLANZAPINE IN 'REVOLVING DOOR' SCHIZOPHRENIC PATIENTS

    Sep 1, 2001, 00:00

  • PAR7- VALIDATION OF A MODEL OF SEVERITY OF ILLNESS IN CHRONIC RESPIRATORY DISEASE

    Sep 1, 2001, 00:00

  • PCN9- COST-EFFECTIVENESS OF IMAGE-GUIDED VERSUS BLIND INSERTION OF HICKMAN LINES IN ADULT CANCER PATIENTS BY NURSES

    Sep 1, 2001, 00:00

  • PHP18- A MODEL FOR COMPARING COSTS ASSOCIATED WITH PRESCRIPTION WASTAGE WITH APPLICATION TO VA PRESCRIPTION DATA

    Sep 1, 2001, 00:00

  • PCN21- HEALTH-RELATED QUALITY OF LIFE AFTER ANDROGEN DEPRIVATION THERAPY IN MEN WITH PROSTATE CANCER

    Sep 1, 2001, 00:00

  • PDG16- BUDGETARY IMPACT OF TREATMENT GUIDELINES-THE EXAMPLE OF TYPE 2 DIABETES

    Sep 1, 2001, 00:00

  • PUR6- THE RELIABILITY AND VALIDITY OF A NEW OAB-SPECIFIC HRQL QUESTIONNAIRE (OAB-Q)

    Sep 1, 2001, 00:00

  • PND3- COST-EFFECTIVENESS OF DEEP BRAIN STIMULATION IN PATIENTS WITH PARKINSONS DISEASE

    Sep 1, 2001, 00:00

  • PMH27- COST-UTILITY ANALYSIS OF QUETIAPINE COMPARED TO RISPERIDONE IN THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA OR OTHER PSYCHOTIC DISORDERS

    Sep 1, 2001, 00:00

  • PCV6- AVAPROMISE- A RANDOMIZED CLINICAL TRIAL FOR INCREASING COMPLIANCE THROUGH BEHAVIORAL MODIFICATION IN ESSENTIAL HYPERTENSION

    Sep 1, 2001, 00:00

  • PCV5- IMPACT OF NON-COMPLIANCE ON THE COSTEFFECTIVENESS OF STATIN THERAPY

    Sep 1, 2001, 00:00

  • PDG13- ASSESSING PATIENT CARE AND COST OF PATIENTS WITH TYPE 2 DIABETES IN GERMANY-AN ANALYSIS ACROSS DIFFERENT TREATMENT TYPES

    Sep 1, 2001, 00:00

  • PWM8- QUALITY OF LIFE IN POST-MENOPAUSAL WOMEN IN FIVE EUROPEAN COUNTRIES

    Sep 1, 2001, 00:00

  • PMI2- SMOOTHED BOOTSTRAP FOR CONFIDENCE INTERVAL FOR COST-EFFECTIVENESS RATIOS

    Sep 1, 2001, 00:00

  • The Excess Cost of Acute Exacerbations of Chronic Bronchitis in Patients Aged 45 and Older in England and Wales

    Sep 1, 2001, 00:00

  • CV4- COMPARISON BETWEEN INVESTIGATOR AND PATIENTS GLOBAL HEALTH ASSESSMENTS USING CALCULATED HUI-III AND SF-36 UTILITY VALUES

    Sep 1, 2001, 00:00

  • CN4- THE IMPACT OF THE DIAGNOSIS OF CANCER ON OUT-OF-POCKET HEALTH-CARE EXPENDITURES MADE BY THE US ELDERLY

    Sep 1, 2001, 00:00

  • PMH25- MENTAL WELL-BEING AMONG CAREGIVERS OF PEOPLE WITH SCHIZOPHRENIA

    Sep 1, 2001, 00:00

  • PAM9- COST COMPARISON OF TREATING RHEUMATOID ARTHRITIS PATIENTS WITH COX-2 INHIBITORS OR NSAIDS IN A MANAGED CARE POPULATION

    Sep 1, 2001, 00:00

  • PMI15- COST ANALYSIS FOR END-OF-LIFE CARE

    Sep 1, 2001, 00:00

  • PAO2- ECONOMIC BURDEN AND LOSS IN QUALITY OF LIFE IN PATIENTS WITH OSTEOARTHRITIS

    Sep 1, 2001, 00:00

  • PKU1- COST-EFFECTIVENESS ANALYSIS OF THREE SURGICAL TREATMENTS FOR FEMALE STRESS URINARY INCONTINENCE

    Sep 1, 2001, 00:00

  • PAR16- COST OF TREATING ASTHMA IN A MANAGED CARE POPULATION

    Sep 1, 2001, 00:00

  • DG3- A RETROSPECTIVE EVALUATION OF NONSTEROIDAL ANTI-INFLAMMATORY DRUG-INDUCED GASTROINTESTINAL COMPLICATIONS AMONG ADULTS IN A MANAGED CARE HEALTH PLAN

    Sep 1, 2001, 00:00

  • PCV12- A COMPARISON OF HEALTH-CARE UTILIZATION AND COSTS OF PATIENTS WITH BRADYCARDIA ONLY AND BRADYCARDIA WITH ATRIAL TACHYARRHYTHMIAS IN THE US, UK AND GERMANY

    Sep 1, 2001, 00:00

  • PGI6- COST-EFFECTIVENESS ANALYSIS OF HELICOBACTER PYLORI ERADICATION TRIPLE THERAPY VERSUS CONVENTIONAL THERAPY FOR GASTRIC AND DUODENAL ULCERS IN JAPAN

    Sep 1, 2001, 00:00

  • PCN17- PSYCHOMETRIC PROPERTIES OF THE EORTC QUALITY OF LIFE CORE QUESTIONNAIRE (QLQ-C30) IN EORTC TRIALS

    Sep 1, 2001, 00:00

  • PMI16- VALUATION OF INFORMAL CARE

    Sep 1, 2001, 00:00

  • PCN13- COST OF THROMBOCYTOPENIA-RELATED BLEEDING AMONG PATIENTS WITH CANCER

    Sep 1, 2001, 00:00

  • PHP7- PILOT STUDY TO DETERMINE THE DEMOGRAPHICS, REASONS, AND TYPES OF MEDICATIONS PURCHASED IN MEXICO BY US RESIDENTS

    Sep 1, 2001, 00:00

  • PDG3- AN ECONOMIC EVALUATION OF COMBINATION THERAPY WITH PIOGLITAZONE (ACTOS, TAKEDA) IN TYPE 2 DIABETES MELLITUS FROM A SPANISH HEALTH-CARE PERSPECTIVE

    Sep 1, 2001, 00:00

  • PAM17- IMPORTANT ISSUES IN NUMBER NEEDED TO TREAT ANALYSIS IN OSTEOPOROSIS TREATMENT

    Sep 1, 2001, 00:00

  • QL4- QUALITY OF LIFE MESSAGES IN PRESCRIPTION DRUG ADVERTISEMENTS IN LEADING MEDICAL JOURNALS, 1990-99

    Sep 1, 2001, 00:00

  • PMA8- DEVELOPMENT OF A CHRONIC DISEASE INDICATOR USING A MANAGED CARE POPULATION

    Sep 1, 2001, 00:00

  • PMH2- IMPROVEMENT IN QUALITY OF LIFE AND DEPRESSIVE SYMPTOMS IN SCHIZOPHRENIC PATIENTS IS ASSOCIATED WITH ROBUST ACUTE TREATMENT RESPONSE OF OLANZAPINE VERSUS HALOPERIDOL

    Sep 1, 2001, 00:00

  • PDG22- EVALUATION OF A GENERIC QOL INSTRUMENT (KINDL) FOR SELF-ASSESSMENT OF QOL IN SINGAPOREAN CHILDREN WITH DIABETES- A PILOT STUDY

    Sep 1, 2001, 00:00

  • PMH24- THE COST OF ACUTE HOSPITALIZATION FOR ANOREXIA NERVOSA AND BULIMIA

    Sep 1, 2001, 00:00

  • PHP14- COST ANALYSIS OF PHARMACEUTICAL SERVICES IN A TEACHING INSTITUTION

    Sep 1, 2001, 00:00

  • PAR11- THE LONG-TERM SOCIETAL ECONOMIC AND HUMANISTIC BENEFITS OF TREATING ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS (AECB) WITH GEMIFLOXACIN VERSUS CLARITHROMYCIN

    Sep 1, 2001, 00:00

  • PRP10- VARIATIONS IN COVERAGE FOR EFFECTIVE SERVICES FOR ASTHMA- IMPACT OF NATIONAL GUIDELINES

    Sep 1, 2001, 00:00

  • PDG6- COST-EFFECTIVENESS OF PIOGLITAZONE (ACTOS, TAKEDA) IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS IN SWEDEN

    Sep 1, 2001, 00:00

  • PWM7- THE EFFECT AND ECONOMIC IMPACT OF STANDARDIZED ORDERS ON THE PREVENTION AND TREATMENT OF PONV IN HOSPITALIZED GYNECOLOGICAL SURGERY PATIENTS

    Sep 1, 2001, 00:00

  • PMH23- THE USE OF NEFAZODONE IN THE TREATMENT OF POST TRAUMATIC STRESS DISORDER

    Sep 1, 2001, 00:00

  • PPN15- MULTIPLE PAIN RELIEF ASSESSMENT IN WOMEN UNDERGOING NATURAL VERSUS EPIDURAL DELIVERY WITH ROPIVACAIN OR BUPIVACAIN

    Sep 1, 2001, 00:00

  • PDG20- A SIMULATION MODEL TO CALCULATE LONGTERM COSTS AND LIFE EXPECTANCY DEPENDENT ON POST PRANDIAL BLOOD GLUCOSE LEVELS IN DIABETES PATIENTS

    Sep 1, 2001, 00:00

  • PDG5- MODELING THE IMPACT OF A NEW ORAL ANTI-DIABETIC TREATMENT ON DIABETES COMPLICATION COSTS IN FRANCE

    Sep 1, 2001, 00:00

  • PAR5- DIRECT AND INDIRECT COSTS OF RESPIRATORY INFECTIONS

    Sep 1, 2001, 00:00

  • PCV7- ENOXAPARIN - A PHARMACOECONOMIC REVIEW OF ITS USE IN ACUTE CORONARY SYNDROMES

    Sep 1, 2001, 00:00

  • PPN10- SURVIVAL AND NURSING HOME FREE SURVIVAL (NHFS) OF AD PATIENTS

    Sep 1, 2001, 00:00

  • PWM4- PHARMACIST-INITIATED EMERGENCY CONTRACEPTION IN BRITISH COLUMBIA

    Sep 1, 2001, 00:00

  • CN4- ECONOMIC EVALUATION OF GEMZAR/CISPLATIN RELATIVE TO OTHER CISPLATIN BASED TREATMENTS FOR NON SMALL CELL LUNG (NSCLC) CANCER IN THE UK

    Sep 1, 2001, 00:00

  • PMH1- RIGOROUS CRITERIA FOR TREATMENT RESPONSE DIFFERENTIATED EFFICACY OF OLANZAPINE VERSUS HALOPERIDOL IN PATIENTS WITH SCHIZOPHRENIA

    Sep 1, 2001, 00:00

  • PEE3- COSTS AND CONSEQUENCES OF OLOPATADINE 0.1 IN THE TREATMENT OF SEASONAL ALLERGIC CONJUNCTIVITIS

    Sep 1, 2001, 00:00

  • PMH6- CHANGE IN INSTRUMENTAL ACTIVITIES OF DAILY LIVING ASSOCIATED WITH ANTIDEPRESSANTS IN OLDER DEPRESSED PATIENTS

    Sep 1, 2001, 00:00

  • CN6- MENS PREFERENCES FOR THE CONSERVATIVE MANAGEMENT OF NON-METASTATIC PROSTATE CANCER- THE USE OF CONJOINT ANALYSIS

    Sep 1, 2001, 00:00

  • PCN10- COST-EFFECTIVENESS MODEL OF PROSTATE-SPECIFIC ANTIGEN (PSA) SCREENING FOR PROSTATE CANCER

    Sep 1, 2001, 00:00

  • PQP5- TRANSLATING SF-36 SCORES INTO PREFERENCES- AN EXAMINATION OF THE PERFORMANCE OF TWO PREDICTIVE EQUATIONS

    Sep 1, 2001, 00:00

  • PID13- ECONOMIC EVALUATION OF ROTAVIRUS VACCINATION FOR THE NETHERLANDS

    Sep 1, 2001, 00:00

  • PCV5- COST OF TREATMENT AND PREVALENCE OF CARDIOVASCULAR DISEASE COMORBIDITIES AND RISK FACTORS IN THE SEVERE AND PERSISTENTLY MENTALLY ILL

    Sep 1, 2001, 00:00

  • PEE6- PROSTAMIDES VS. COMBINATION PRODUCTS FOR GLAUCOMA TREATMENT- EFFECTIVENESS AND COST CONSIDERATIONS

    Sep 1, 2001, 00:00

  • PHP7- APPLICATION OF HEALTH ECONOMICS IN THE CANADIAN PHARMACEUTICAL INDUSTRY

    Sep 1, 2001, 00:00

  • CV4- USING UK OBSERVATIONAL DATA TO IDENTIFY POSSIBILITIES FOR THE COST-EFFECTIVE IMPROVEMENT OF THE TREATMENT OF ATRIAL FIBRILLATION

    Sep 1, 2001, 00:00

  • PCV23- PHARMACOECONOMIC EVALUATION OF USAGE OF UNFRACTIONATED HEPARIN AND LOW MOLECULAR WEIGHT HEPARIN IN THE TREATMENT OF DEEP VEIN THROMBOSIS IN LONG-TERM CARE RESIDENTS

    Sep 1, 2001, 00:00

  • QL3- PSYCHOMETRIC PERFORMANCE OF THE MEDICAL OUTCOMES STUDY SLEEP SCALE IN THE US GENERAL POPULATION

    Sep 1, 2001, 00:00

  • PAR13- HYPOTHETICAL VERSUS REAL WILLINGNESS TO PAY IN THE HEALTH CARE SECTOR- RESULTS FROM A FIELD EXPERIMENT

    Sep 1, 2001, 00:00

  • PIN19- POTENTIAL USE OF FLUOROQUINOLONES IN THE TREATMENT OF PULMONARY TUBERCULOSIS

    Sep 1, 2001, 00:00

  • CH3- TRENDS IN POPULATION-BASED HEALTH-RELATED QUALITY OF LIFE- IMPLICATIONS FOR INTERPRETATION OF CHANGE

    Sep 1, 2001, 00:00

  • PHP18- THE CLINICAL PHARMACIST AS A MEMBER OF THE MEDICAL WARD TEAM-A PILOT STUDY

    Sep 1, 2001, 00:00

  • PID14- PREDICTORS OF THE MENTAL (MHS) AND PHYSICAL HEALTH SUMMARY (PHS) SCORES OF THE MOS-HIV IN A SAMPLE OF HIV-INFECTED PATIENTS

    Sep 1, 2001, 00:00

  • PDB8- FACTORS ASSOCIATED WITH PRESCRIPTION CLAIMS FOR BLOOD GLUCOSE TEST STRIPS AMONG FEE-FOR-SERVICE NEW MEXICO MEDICAID PATIENTS

    Sep 1, 2001, 00:00

  • PCN11- COST-EFFECTIVENESS OF SENTINEL LYMPH NODE MAPPING AND ADJUVANT INTERFERON THERAPY FOR STAGE II MELANOMA

    Sep 1, 2001, 00:00

  • MD3- THE DIAGNOSTIC ACCURACY OF 18FDG-PET IN PATIENTS WITH RECURRENT PAPILLARY OR FOLLICULAR THYROID CANCER- A SYSTEMATIC REVIEW

    Sep 1, 2001, 00:00

  • PAR21- LEVALBUTEROL USE IS ASSOCIATED WITH DECREASED HEALTH CARE COSTS IN PATIENTS WITH MORE SEVERE ASTHMA

    Sep 1, 2001, 00:00

  • PHP8- PRACTICE USE OF PHARMACOECONOMICS DATA IN HOSPITAL FORMULARY DECISIONS

    Sep 1, 2001, 00:00

  • PQP1- LESSONS LEARNED FROM DEVELOPING A PSYCHOMETRICALLY BASED SEDATION QUESTIONNAIRE IN PHARMACOLOGICALLY PARALYZED CRITICALLY ILL PATIENTS

    Sep 1, 2001, 00:00

  • PCV32- DEVELOPMENT OF TWO INSTRUMENTS- ONE TO MEASURE EDUCATIONAL MATERIAL ACCEPTABILITY AND ONE TO MEASURE KNOWLEDGE GAINED IN PATIENTS WITH HEART FAILURE

    Sep 1, 2001, 00:00

  • RP3- PREPARING THE ASTHMA SYMPTOM UTILITY INDEX FOR INTERNATIONAL USE- TRANSLATION AND LINGUISTIC VALIDATION

    Sep 1, 2001, 00:00

  • PHP22- PATIENT ADHERENCE TO DRUG THERAPY IN A THREE-TIER COPAYMENT STRUCTURE

    Sep 1, 2001, 00:00

  • MH4- SLEEP DISORDERS AND HEALTH RELATED QUALITY OF LIFE-AN EPIDEMIOLOGICAL SURVEY

    Sep 1, 2001, 00:00

  • PMH26- OUTPATIENT ANTIPSYCHOTIC USE- COMPARING ATYPICAL AND CONVENTIONAL ANTIPSYCHOTIC ADHERENCE USING A NATIONAL RETAIL PHARMACY DATA BASE

    Sep 1, 2001, 00:00

  • PMI13- A COMPARISON OF EQ-5D TIME TRADE-OFF VALUES OBTAINED IN GERMANY, UK AND SPAIN- COULD THERE BE ONE EUROPEAN EQ TARIFF?

    Sep 1, 2001, 00:00

  • PUR5- THE IMPACT OF PHARMACOTHERAPY ON OVERACTIVE BLADDER SYMPTOM IMPROVEMENT AND RESOURCE UTILIZATION

    Sep 1, 2001, 00:00

  • Cost-Effectiveness Analysis of Entacapone in Parkinson's Disease- A Markov Process Analysis

    Jul 1, 2001, 00:00

  • Assessment of Clinical Guidelines for Continuation Treatment in Major Depression

    Jul 1, 2001, 00:00

  • Measuring Up to the Task

    Jul 1, 2001, 00:00

  • Long-Term Costs of Treatment for Depression- Impact of Drug Selection and Guideline Adherence

    Jul 1, 2001, 00:00

  • Implications of Controlling for Comorbid Conditions in Cost-of-Illness Estimates- A Case Study of Osteoarthritis from a Managed Care System Perspective

    Jul 1, 2001, 00:00

  • Letter From Mr. Patrick Marquis

    Jul 1, 2001, 00:00

  • Reproducibility and Clinical and Concurrent Validity of the MSF-4- A Four-Item Male Sexual Function Questionnaire for Patients with Benign Prostatic Hyperplasia

    Jul 1, 2001, 00:00

  • Cost-Effectiveness of Pergolide Compared to Bromocriptine in the Treatment of Parkinson's Disease- A Decision-Analytic Model

    Jul 1, 2001, 00:00

  • Implications of the Appraisal Function of the National Institute for Clinical Excellence (NICE)

    May 1, 2001, 00:00

  • The Outpatient Cost of Diabetes Care in Italian Diabetes Centers

    May 1, 2001, 00:00

  • Pharmacoeconomic Guidelines- Where Do We Go from Here?

    May 1, 2001, 00:00

  • Cost-Effectiveness of Partner Pharmacotherapy in Screening Women for Asymptomatic Infection with Chlamydia Trachomatis

    May 1, 2001, 00:00

  • Average National Payments

    May 1, 2001, 00:00

  • Health Economic Guidelines—Similarities, Differences and Some Implications

    May 1, 2001, 00:00

  • Diabetes in Canada- Direct Medical Costs of Major Macrovascular Complications

    May 1, 2001, 00:00

  • The Role of the World Health Organization on Pharmaceuticals in Europe

    May 1, 2001, 00:00

  • Letter from M. Berger

    May 1, 2001, 00:00

  • Modeling Choice Behavior for New Pharmaceutical Products

    Jan 1, 2001, 00:00

  • Addendum

    Jan 1, 2001, 00:00

  • Regulation of Pharmacoeconomics and Outcomes Research Presented at the ISPOR 5th Annual International Meeting, Crystal City, VA, 24 May 2000

    Jan 1, 2001, 00:00

  • A Multinational Pharmacoeconomic Evaluation of Acute Major Depressive Disorder (MDD)- a Comparison of Cost-Effectiveness Between Venlafaxine, SSRIs and TCAs

    Jan 1, 2001, 00:00

  • US Regulation of Pharmaceutical Outcomes Research Presented at the ISPOR 5th Annual International Meeting, Crystal City, VA, 24 May 2000

    Jan 1, 2001, 00:00

  • Renewal of Our Value in Health Mission and Policy As We Enter Our Fourth Year

    Jan 1, 2001, 00:00

  • Pharmaceutical Regulation- The Early Experience of the NHS National Institute for Clinical Excellence (NICE) Appraisal Process—Where Are We Headed? Presented at the ISPOR 5th Annual International Meeting, Crystal City, VA, 24 May 2000

    Jan 1, 2001, 00:00

  • Predictors of Long-term Persistence on Statins in a Subsidized Clinical Population

    Nov 1, 2000, 00:00

  • Short–run Associations Between Medical Care Expenditures and Adherence to Clinical Practice Guideline-based Measures for Diabetes

    Nov 1, 2000, 00:00

  • Deep Vein Thrombosis- Cost-effective Management of a Major Health Problem

    Nov 1, 2000, 00:00

  • Health-Related Quality of Life Measurement in Type 2 Diabetes

    Nov 1, 2000, 00:00

  • Introduction to Diabetes Special Issue of Value in Health

    Nov 1, 2000, 00:00

  • Economic Evaluation of Enoxaparin vs. Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients

    Nov 1, 2000, 00:00

  • Economic Evaluations Relating to Diabetes- A Descriptive Review and Their Compliance with Guidance

    Nov 1, 2000, 00:00

  • The Cost-effectiveness of Treating Diabetic Lower Extremity Ulcers with Becaplermin (Regranex)- A Core Model with an Application Using Swedish Cost Data

    Nov 1, 2000, 00:00

  • Health-related Quality of Life in Type 2 Diabetes (TARDIS-2)

    Nov 1, 2000, 00:00

  • Early Modelling for Assessing Health and Economic Outcomes of Drug Therapy

    Nov 1, 2000, 00:00

  • Second Line Pharmacological Management of Paroxysmal and Persistent Atrial Fibrillation in France- A Cost Analysis

    Nov 1, 2000, 00:00

  • Epidemiology and Clinical Presentation of Type 2 Diabetes

    Nov 1, 2000, 00:00

  • Economic Evaluation of Enoxaparin as Postdischarge Prophylaxis for Deep Vein Thrombosis (DVT) in Elective Hip Surgery

    Nov 1, 2000, 00:00

  • GU2- HEALTH CARE WORKERS EXPECTATIONS

    Sep 1, 2000, 00:00

  • PMDP3- THE FRENCH HEALTH UTILITIES INDEX MARK 3

    Sep 1, 2000, 00:00

  • PMDQ1- GENERAL POPULATION-BASED QUALITY OF LIFE MEASUREMENTS USING THE EQ-5D QUESTIONNAIRE

    Sep 1, 2000, 00:00

  • PMDE1- SOCIETAL IMPACT OF LOST EARNINGS ASSOCIATED WITH AGE-RELATED MACULOPATHY

    Sep 1, 2000, 00:00

  • PAO1- COST-EFFECTIVENESS ANALYSIS OF NSAIDS VS COX-2 SPECIFIC INHIBITORS AND NSAIDS WITH CO-TREATMENTS TO PREVENT Gl TOXICITY IN THE TREATMENT OF RA

    Sep 1, 2000, 00:00

  • NR2- QUALITY OF LIFE AFTER SUBARACHNOID HEMORRHAGE IN RELATION TO RISK ESTIMATION BEFORE SURGERY

    Sep 1, 2000, 00:00

  • PAO3- DIRECT MEDICAL COST OF CHRONIC POLYARTHRITIS IN GERMANY

    Sep 1, 2000, 00:00

  • RS2- SYMPTOM-BASED OUTCOME MEASURES FOR ASTHMA

    Sep 1, 2000, 00:00

  • PCV29- SUPPORTING IMPLEMENTATION OF PRESCRIPTION GUIDELINES IN MEDICAL WARDS- A RANDOMIZED TRIAL

    Sep 1, 2000, 00:00

  • PGS5- APPRAISAL OF ERECTILE DYSFUNCTION- WHOSE VALUES SHOULD BE USED?

    Sep 1, 2000, 00:00

  • AO2- GENERIC AND DISEASE-SPECIFIC HEALTH RELATED QUALITY OF LIFE MEASUREMENTS IN 127 RHEUMATOID ARTHRITIS AND 167 OSTEOARTHRITIS PATIENTS IN HUNGARY

    Sep 1, 2000, 00:00

  • CV4- THE INFLUENCE OF NON-CARDIAC VASCULAR DISEASE ON THE COST-EFFECTIVENESS OF SCREENING FOR LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (LVSD)

    Sep 1, 2000, 00:00

  • PNR5- THE LONG-TERM ECONOMIC IMPACT OF TREATING ALZHEIMERS PATIENTS IN SWEDEN WITH GALANTAMINE

    Sep 1, 2000, 00:00

  • PMDP1- WILLINGNESS TO PAY FOR AVOIDING ADVERSE EFFECTS OF DRUGS

    Sep 1, 2000, 00:00

  • PRS3- EUROQOL EQ-5D- DISCRIMINANT VALIDITY IN RESPIRATORY DISEASE

    Sep 1, 2000, 00:00

  • PMDQ3- HEALTH-RELATED QUALITY OF LIFE AMONG FRENCH PATIENTS HOSPITALIZED IN INTERNAL MEDICINE

    Sep 1, 2000, 00:00

  • PNH6- ANTIPSYCHOTIC TREATMENT, ADVERSE EVENTS AND HEALTH-RELATED QUALITY OF LIFE

    Sep 1, 2000, 00:00

  • PRS9- PROBLEMATIC ISSUES OF THE QUALITY OF ASTHMA MANAGEMENT IN RURAL AREAS IN GREECE

    Sep 1, 2000, 00:00

  • PCV9- PROPHYLAXIS AGAINST DEEP-VEIN THROMBOSIS AND FATAL PULMONARY EMBOLISM IN KNEE ARTHROPLASTIES- A COST-EFFECTIVENESS STUDY

    Sep 1, 2000, 00:00

  • PRS7- AN ECONOMIC IMPACT OF A DUR INTERVENTION ON THE PHARMACOLOGICAL MANAGEMENT OF ASTHMA IN CHILDREN

    Sep 1, 2000, 00:00

  • PNR7- COST-EFFECTIVENESS ANALYSIS OF ENTACAPONE IN ADVANCED PARKINSONS DISEASE A MARKOV PROCESS ANALYSIS

    Sep 1, 2000, 00:00

  • PMH15- ECONOMIC EVALUATION OF REBOXETINE FOR TREATING MAJOR DEPRESSION

    Sep 1, 2000, 00:00

  • PMDP4- THE INFLUENCE OF NON-COMPLIANCE ON THE EFFECTIVENESS AND COST-EFFECTIVENESS OF DRUG THERAPIES

    Sep 1, 2000, 00:00

  • PCV5- ECONOMIC EVALUATION OF RAMIPRIL IN THE TREATMENT OF PATIENTS AT HIGH RISK OF CARDIOVASCULAR EVENTS

    Sep 1, 2000, 00:00

  • PCV1- THE ATRIAL FIBRILLATION ANTITHROMBOSIS MODEL (AFAM)- A GENERAL-PURPOSE TOOL FOR ANALYSIS, POLICY-MAKING, AND EDUCATION

    Sep 1, 2000, 00:00

  • PCN12- CHANGES IN OUTPATIENT DRUG COSTS FOR CANCER PATIENTS, 1995 vs 1998

    Sep 1, 2000, 00:00

  • PID7- MULTITHERAPIES- TOWARDS COST-SAVING STRATEGIES IN REAL LIFE?

    Sep 1, 2000, 00:00

  • CV2- EFFECTIVENESS AND COST-EFFECTIVENESS OF EPTIFIBATIDE IN INDIVIDUAL PATIENTS WITH ACUTE CARDIAC ISCHEMIA- THE IMPORTANCE OF RISK STRATIFICATION

    Sep 1, 2000, 00:00

  • CV6- A MULTICENTER STUDY OF PHARMACIST DIRECTED INTERVENTIONS IN DYSLIPIDEMIA THERAPY

    Sep 1, 2000, 00:00

  • PNR6- SUBJECTIVE AND OBJECTIVE QUALITY OF LIFE CHANGE SCORES IN A SHORT-TERM EPILEPSY STUDY

    Sep 1, 2000, 00:00

  • PGU3- DECISION ANALYSIS OF OMEPRAZOLE VERSUS LAPAROSCOPIC NISSEN FUNDOPLICATION FOR TREATING PATIENTS WITH SEVERE GASTROESOPHAGEAL REFLUX DISEASE

    Sep 1, 2000, 00:00

  • PID6- CANADIAN COST-EFFECTIVENESS OF COMBINATION RIBAVIRIN/INTERFERON ALPHA-2B THERAPY FOR TREATMENT-NAIVE VIRAL HEPATITIS C

    Sep 1, 2000, 00:00

  • PMDP2- CONSUMER USE OF THE INTERNET FOR HEALTHCARE INFORMATION

    Sep 1, 2000, 00:00
  • «
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178 (current)
  • 179
  • 180
  • »